Piramal Pharma · NSE: PPLPHARMA · BSE: 543635
Q1 FY24 results · Apr–Jun 2023
Piramal Pharma reported revenue from operations of ₹1,748.85 crore and net loss of ₹98.58 crore for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,748.85 | — | — | 2,163.58 | −19.2% |
| Other income | 38.31 | — | — | 24.50 | +56.4% |
| Total income | 1,787.16 | — | — | 2,188.08 | −18.3% |
| Profit before share of associates & JVs and tax | (121.50) | — | — | 87.11 | Turned loss |
| Share of profit/(loss) of associates & JVs | 14.39 | — | 7.78 | ||
| Net profit for the period | (98.58) | — | — | 50.11 | Turned loss |
| EPS, basic (₹) | (0.83) | — | — | 0.42 | Turned loss |
| Net margin (%) | -5.6 | — | 2.3 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 846.43 | — | — | 1,054.58 | −19.7% |
| Other income | 26.68 | — | — | 62.88 | −57.6% |
| Total income | 873.11 | — | — | 1,117.46 | −21.9% |
| Profit before tax | (40.90) | — | — | 65.64 | Turned loss |
| Net profit for the period | (33.36) | — | — | 41.70 | Turned loss |
| EPS, basic (₹) | (0.28) | — | — | 0.35 | Turned loss |
| Net margin (%) | -3.9 | — | 4.0 |
Consolidated
- Filed with BSE
- 03 Aug 2023, 21:32 IST
- Board meeting
- 03 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Aug 2023, 21:32 IST
- Board meeting
- 03 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE